Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

IRMDBullishEarningsShort Term

High materiality9/10

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

StockNews.AIJul 31, 8:15 AM EDT1 source

Trading thesisImportance 9/10

IRMD could trend higher in 3–6 months as the 3870 ramp accelerates.

AI summary

What happened and why it matters

IRADIMED CORPORATION reported Q2 2026 revenue of $20.5 million, up 0.5% year over year, with GAAP EPS of $0.41 and non-GAAP EPS of $0.46. The company declared a quarterly dividend of $0.20 per share and reaffirmed full-year 2026 guidance of $91–$96 million in revenue and $1.90–$2.05 in GAAP EPS ($2.09–$2.24 non-GAAP). The highlight is progress on the 3870 MR IV pump ramp and record domestic monitor bookings, implying improving mix and potential margin upside in H2.

3870 MR IV pump ramp could lift near-term revenue and gross margins.
Record domestic monitor bookings signal stronger MRI-related demand.
Dividend declaration supports income-focused investors; no yield change.
Guidance reaffirmed, reducing downside risk into 2H 2026.

Sentiment rationale

The Q2 results align with expectations; the 3870 ramp and quad-stack adoption point to stronger demand and potential gross-margin improvement in H2, supporting a near-term upside. The dividend and reaffirmed guidance reduce downside risk, though execution risk around ramp speed remains a consideration; historical IRMD reactions tend to move on progress of new platforms and bookings velocity.

Key facts

01
Q2 2026 revenue $20.5m. Up 0.5% YoY.
02
GAAP EPS: $0.41. Non-GAAP EPS: $0.46.
03
Dividend: $0.20 per share. Payable Aug 28, 2026.
04
3870 MR IV pump ramp underway. Quad-stack orders >70%.
05
Full-year 2026: revenue $91–96m; GAAP EPS $1.90–2.05.

Earnings

Category: Earnings. This release combines a quarter’s results with an ongoing product ramp and a dividend declaration, reinforcing the growth narrative around the 3870 platform while maintaining a conservative view on near-term margins.